Physician profile
David Davis
NPI 1225484975
$34,230.80
in general payments reported to CMS, 2019-2025
26 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,644 · 2022: $17K · 2023: $7,676 · 2024: $415 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,600 · Food and Beverage: $1,553 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,600.00 |
| Food and Beverage | $1,553.15 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19,787.63 | 2021-2024 | Minimed 780g, Minimed 770g |
| Insulet Corporation | $10,554.07 | 2021-2023 | Omnipod |
| Amgen INC. | $987.69 | 2021-2023 | Repatha, Otezla |
| Novo Nordisk INC | $591.51 | 2021-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $280.51 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $249.51 | 2021-2023 | |
| Esperion Therapeutics, INC. | $219.79 | 2021-2022 | |
| Mannkind Corporation | $213.26 | 2021-2023 | Afrezza |
| Dexcom, INC. | $210.27 | 2021-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $195.71 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $166.20 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $134.37 | 2022-2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $132.25 | 2021-2023 | |
| Halozyme INC | $69.73 | 2023 | |
| Merck Sharp & Dohme LLC | $69.65 | 2021-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $54.19 | 2022-2024 | |
| Ascendis Pharma Endocrinology INC | $49.62 | 2025 | Yorvipath |
| Nevro Corp. | $46.66 | 2021-2023 | Senza |
| Tandem Diabetes Care, INC. | $41.41 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals Lp | $37.36 | 2021-2022 | |
| Horizon Therapeutics Plc | $28.65 | 2023 | Tepezza |
| Pfizer INC. | $26.98 | 2023 | |
| Sumitomo Pharma America, INC. | $24.06 | 2023 | Gemtesa |
| Antares Pharma, INC. | $21.82 | 2023 | Nocdurna, Tlando, Xyosted |
| Radius Health, INC. | $19.05 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.